GS-US-595-6184 A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

  • Phase III
  • Trial Category: Breast

Contact(s)

Mary Beth Wilwerding, RN   Admin@NEcancertrials.com

Location(s)

Available at Nebraska Cancer Specialists Omaha locations, and Nebraska Methodist Estabrook Cancer Center, Omaha, NE

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*